Partner Headlines - EXEL

  1. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  2. 5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic ...

    GuruFocus
  3. Mid-Day Market Update: ON Semiconductor Surges On $1 Billion ...

    Benzinga
  4. Mid-Morning Market Update: Markets Open Lower; Weatherford To ...

    Benzinga
  5. Morning Market Losers

    Benzinga
  6. Events for the Week of Nov. 17-21, 2014

    Benzinga
  7. Morning Market Movers

    Benzinga
  8. 5-year lows: National Presto Industries, Ennis Inc, Landauer ...

    GuruFocus
  9. Stocks Hitting 52-Week Lows

    Benzinga
  10. Equities, Commodities & Bonds Finish Lower On First Trading Day ...

    Benzinga
  11. Midday Losers From Tuesday, September 2

    Benzinga
  12. Exelixis Shares Slide On Trial Results; Norwegian Cruise Line ...

    Benzinga
  13. Markets Mixed; Conn's Profit Misses Estimates

    Benzinga
  14. Stocks Hitting 52-Week Lows

    Benzinga
  15. Morning Market Losers

    Benzinga
  16. Benzinga's Top Downgrades

    Benzinga
  17. Stifel Nicolaus Downgrades Exelixis To Hold

    Benzinga
  18. Stocks To Watch For September 2, 2014

    Benzinga
  19. Exelixis Announces Results From COMET-1 Phase 3 Pivotal Trial ...

    Benzinga
  20. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; ...

    Benzinga
  21. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga
  22. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit ...

    Benzinga
  23. Morning Market Movers

    Benzinga
  24. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga
  25. Benzinga's Top #PreMarket Gainers

    Benzinga
  26. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  27. Benzinga's Top #PreMarket Gainers

    Benzinga
  28. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian ...

    GuruFocus
  29. Market Wrap For March 26: Markets Close Near Session Lows In ...

    Benzinga
  30. Mid-Afternoon Market Update: Markets Turn Red as Dish Network ...

    Benzinga
  31. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis ...

    Benzinga
  32. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues ...

    Benzinga
  33. Stocks Hitting 52-Week Lows

    Benzinga
  34. Morning Market Losers

    Benzinga
  35. Benzinga's Top #PreMarket Losers

    Benzinga
  36. Morning Market Movers

    Benzinga
  37. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  38. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  39. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  40. Exelixis Announces Promising Phase 1b Data for Cobimetinib in ...

    Benzinga
  41. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  42. Exelixis Announces Full Patient Enrollment for COMET-1 Phase ...

    Benzinga
  43. US Stock Futures Up After Upbeat China Data

    Benzinga
  44. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  45. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga
  46. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  47. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort ...

    Benzinga
  48. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FoxBusiness
  49. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  50. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga
  51. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  52. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FoxBusiness
  53. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga
  54. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  55. Health Care Sector Wrap

    FoxBusiness
  56. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FoxBusiness
  57. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  58. UPDATE: Exelixis Announces Proposed Convertible Debt Offering ...

    Benzinga
  59. Exelixis Proposed Offering 20M Shares

    Benzinga
  60. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  61. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  62. Benzinga's Top Pre-Market Gainers

    Benzinga
  63. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga
  64. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored ...

    Benzinga
  65. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  66. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga
  67. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga
  68. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily ...

    Benzinga
  69. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
  70. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival ...

    Benzinga
  71. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga
  72. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    Benzinga
  73. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  74. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    Benzinga
  75. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    MarketIntelligenceCenter
  76. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    Benzinga
  77. Exelixis Announces Proposed Public Offering of 10M Shares

    Benzinga
  78. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data ...

    Benzinga
  79. Notable Call Options Activity on Exelixis

    Benzinga
  80. Exelixis Trading Higher After Licensing Agreement with Merck

    Benzinga
  81. Exelixis Lures Premium Sellers on Positive Drug Data

    SchaeffersResearch
Trading Center